The Effects of Testosterone on Cervicovaginal Cytology in Transgender and Gender-Diverse Individuals

References

1. 1.↵
   1. Perkins RB,
   2. Guido RS,
   3. Castle PE

   , 2019 ASCCP Risk-Based Management Consensus Guidelines Committeeet al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24:102–31.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Torous VF

   . Cervicovaginal Papanicolaou tests in transgender men: cytomorphologic alterations, interpretation considerations, and clinical implications. Cancer Cytopathol 2023;131:626–36.

   OpenUrlPubMed
3. 3.↵
   1. Panichella JC,
   2. Araya S,
   3. Nannapaneni S,
   4. et al

   . Cancer screening and management in the transgender population: review of literature and special considerations for gender affirmation surgery. World J Clin Oncol 2023;14:265–84.

   OpenUrlPubMed
4. 4.↵
   1. Williams MPA,
   2. Kukkar V,
   3. Stemmer MN,
   4. Khurana KK

   . Cytomorphologic findings of cervical Pap smears from female-to-male transgender patients on testosterone therapy. Cancer Cytopathol 2020;128:491–8.

   OpenUrlPubMed
5. 5.↵
   1. Moatamed NA,
   2. Barco A,
   3. Del Yang S,
   4. et al

   . Clinical history of female‐to‐male transgender patients is needed to avoid misinterpretation of cervical Papanicolaou tests. Cytopathology 2023;34:120–9.

   OpenUrlPubMed
6. 6.↵
   1. Davis K,
   2. Kwon R,
   3. Graham A,
   4. White M,
   5. Maleki Z,
   6. Rodriguez E

   . Comparison of cervical cancer screen results on female-to-male transgender patients with female patients. Am J Clin Pathol 2022;157:540–5.

   OpenUrlPubMed
7. 7.↵
   1. Adkins BD,
   2. Barlow AB,
   3. Jack A,
   4. et al

   . Characteristic findings of cervical Papanicolaou tests from transgender patients on androgen therapy: challenges in detecting dysplasia. Cytopathology 2018;29:281–7.

   OpenUrlPubMed
8. 8.↵
   1. Peitzmeier SM,
   2. Reisner SL,
   3. Harigopal P,
   4. Potter J

   . Female-to-male patients have high prevalence of unsatisfactory paps compared to non-transgender females: implications for cervical cancer screening. J Gen Intern Med 2014;29:778–84.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Ahmad S,
   2. Leinung M

   . The response of the menstrual cycle to initiation of hormonal therapy in transgender men. Transgend Health 2017;2:176–9.

   OpenUrlPubMed
10. 10.↵
    1. Maraqa B,
    2. Lataifeh I,
    3. Otay L,
    4. et al

    . Prevalence of abnormal pap smears: a descriptive study from a cancer center in a low-prevalence community. Asian Pac J Cancer Prev 2017;18:3117–21.

    OpenUrlPubMed
11. 11.↵
    1. Arslan E,
    2. Gokdagli F,
    3. Bozdag H,
    4. Vatansever D,
    5. Karsy M

    . Abnormal Pap-smear frequency and comparison of repeat cytological follow-up with colposcopy during patient management: the importance of pathologist’s guidance in the management. North Clin Istanb 2019;6:69–74.

    OpenUrlPubMed
12. 12.↵
    1. Wang JC,
    2. Peitzmeier S,
    3. Reisner SL,
    4. et al

    . Factors associated with unsatisfactory pap tests among sexually active trans masculine adults. LGBT Health 2023;10:278–86.

    OpenUrlPubMed
13. 13.↵
    1. Tordoff DM,
    2. Lunn MR,
    3. Chen B,
    4. et al

    . Testosterone use and sexual function among transgender men and gender diverse people assigned female at birth. Am J Obstet Gynecol 2023;229:669.e1–669.e17.

    OpenUrlPubMed
14. 14.↵
    1. Krakowsky Y,
    2. Potter E,
    3. Hallarn J,
    4. et al

    . The effect of gender-affirming medical care on the vaginal and neovaginal microbiomes of transgender and gender-diverse people. Front Cell Infect Microbiol 2021;11:769950.

    OpenUrlPubMed
15. 15.↵
    1. Defreyne J,
    2. Elaut E,
    3. Kreukels B,
    4. et al

    . Sexual desire changes in transgender individuals upon initiation of hormone treatment: results from the Longitudinal European Network for the Investigation of Gender Incongruence. J Sex Med 2020;17:812–25.

    OpenUrlPubMed
16. 16.↵
    1. Polanco Jacome EC,
    2. Maerki J,
    3. Chau K,
    4. et al

    . Lack of transformation zone in cervical Pap tests, should it be a concern? A quality assurance initiative. Diagn Cytopathol 2018;46:584–8.

    OpenUrlPubMed
17. 17.↵
    1. Elumir-Tanner L,
    2. Doraty M

    , Southern Alberta Primary Care Research Network (SAPCReN). Management of Papanicolaou test results that lack endocervical cells. CMAJ 2011;183:563–8.

    OpenUrlFREE Full Text
18. 18.
    1. Downs LS,
    2. Nayar R,
    3. Gerndt J,
    4. Saslow D

    , American Cancer Society Primary HPV Screening Initiative Steering Committee. Implementation in action: collaborating on the transition to primary HPV screening for cervical cancer in the United States. CA Cancer J Clin 2023;73:458–60.

    OpenUrlPubMed
19. 19.
    1. Linder M

    . Absent transformation zone. Published online 2021:1–2. Available at: https://www.asccp.org/Assets/888a04ee-f6e2-4f70-886d-6c1485480ec8/637558111538770000/asccp-pearls-absent-transformation-zone-final-pdf.
20. 20.↵
    1. Pimple S,
    2. Mishra G

    . Cancer cervix: epidemiology and disease burden. Cytojournal 2022;19:21.

    OpenUrlPubMed